Clinical Trials Sponsored by Eisai Limited

Total 3595 results

Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-

Alzheimer's Disease

Japan
Eisai Co., Ltd.

Completed

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

Stomach Ulcer

Japan
Eisai Co., Ltd.

Completed

Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects

Healthy Participants

Japan
Eisai Inc.
Eisai Co., Ltd.

Completed

Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism

Pulmonary Embolism

Japan
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice

Alzheimer's Disease

Japan
Eisai Co., Ltd.

Completed

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

Insomnia

Japan
Eisai Co., Ltd.

Completed

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Healthy Subjects

China
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A

Cervical Dystonia

Japan
Eisai Co., Ltd.

Completed

A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

Down Syndrome

Japan
Eisai Co., Ltd.

Completed

Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)

Malignant Glioma

Japan
Eisai Co., Ltd.

Completed

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

Solid Tumor

Japan
Eisai Co., Ltd.

Completed

A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer

Breast Cancer

Japan
Eisai Korea Inc.

Completed

Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease (SAVE)

Alzheimer's Disease

Korea, Republic of
Eisai Co., Ltd.

Completed

A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation

Hypervascular Tumor and Arteriovenous Malformation

Japan
Eisai Co., Ltd.

Completed

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

Healthy Subjects

Japan
Eisai Co., Ltd.

Completed

Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects

Healthy Volunteers

Japan
Eisai Co., Ltd.

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects

Healthy Subjects

Japan
Eisai Co., Ltd.

Completed

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Japan
Eisai Co., Ltd.

Completed

Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Japan
Eisai Co., Ltd.

Completed

A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

Dementia With Lewy Bodies (DLB)
Eisai Co., Ltd.

Completed

Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom

Chronic Obstructive Pulmonary Disease | Asthma

Japan
Eisai Inc.
Eisai Farmacêutica S.A.

Completed

ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs

Epilepsy

Spain
Eisai Co., Ltd.

Completed

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

Coronary Artery Disease

Japan
Eisai Co., Ltd.

Completed

Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer

Gastric Ulcer | Acute Gastritis

China
Eisai Co., Ltd.

Completed

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

Dementia With Lewy Bodies (DLB)

Japan
Eisai Co., Ltd.

Completed

A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

Primary Insomnia

Japan
Eisai Co., Ltd.

Completed

A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

Insomnia

Japan
Eisai Co., Ltd.

Completed

A Bioequivalence Study Comparing Improved Versus Current Orally Disintegrating E2020 10 mg Tablet in Healthy Japanese Adult Males

Healthy Adult

Japan
Eisai Co., Ltd.

Completed

E2022 Patch Formulation Multiple Dose Study

Healthy

Japan
Eisai Co., Ltd.

Completed

Phase I Clinical Study of E7389

Cancer

Japan
Eisai Co., Ltd.

Completed

A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males

Healthy Adult

Japan
Eisai Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

Japan
Eisai Korea Inc.

Completed

A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Carcinoma | Renal Cell Carcinoma | Endometrial Neoplasms | Endometrium

Korea, Republic of
Eisai Co., Ltd.

Active, not recruiting

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Solid Tumor

Japan
Eisai Co., Ltd.

Active, not recruiting

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Breast Neoplasms

Japan
Eisai Co., Ltd.

Completed

A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants

Healthy Volunteers

Japan
Eisai Co., Ltd.

Completed

A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants

Healthy Volunteers

China
Eisai Co., Ltd.

Completed

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Inoperable or Recurrent Breast Cancer

Japan
Eisai Co., Ltd.

Completed

A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients

Gastroesophageal Reflux Disease

Japan
Eisai Co., Ltd.

Completed

A Study of E7080 in Subjects With Solid Tumor

Cancer

Japan
Eisai Co., Ltd.

Completed

A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males

Healthy Elderly Male

Japan
Eisai Korea Inc.

Completed

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

Carcinoma, Hepatocellular | Liver Neoplasms

Korea, Republic of
Eisai Co., Ltd.

Active, not recruiting

A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)

Parkinson Disease

Japan
Eisai Korea Inc.

Completed

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-remitting

Korea, Republic of
Eisai Co., Ltd.

Completed

A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

Sleep Initiation and Maintenance Disorders

Japan
Eisai Co., Ltd.

Completed

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures (FYC01S)

Partial Seizures (With or Without Secondary Generalized Seizures) | Primary Generalized Tonic-clonic Seizures

Japan
Eisai Co., Ltd.

Completed

A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants

Healthy Participants

Japan
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

Solid Tumor

China
Eisai Co., Ltd.

Completed

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Japan, Korea, Republic of

3

Subscribe